TheaDesign A ruling by a judge in a Delaware court will allow Exact Sciences ( NASDAQ: EXAS ) to proceed with its case against Geneoscopy over patent infringement and false advertising accusations. Geneoscopy had sought to dismiss the case filed in November 2023. Exact Sciences markets the Cologuard colorectal cancer screening test, while Geneoscopy sells the rival ColoSense.
Exact Sciences now has two complaints against Geneoscopy, the latest filed on May 15 in regard to another patent. The patents in both cases involve "novel sample collection technologies," according to a news release . The first case was also brought to "put an end to Geneoscopy’s false and misleading advertising and promotion about the alleged clinical performance and superiority of ColoSense," Exact Sciences ( EXAS ) noted.
More on Exact Sciences Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau Most attractive short-term overwriting stocks for June expiration - Goldman Exact Sciences down 17% on quarterly bottom line miss, maintaining 2024 guidance Exact Sciences Corporation (EXAS) Q4 2023 Earnings Call Transcript Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript.
